Tag: PET imaging for neuroendocrine tumors
Detectnet (copper Cu 64 dotatate injection) Now Included in NCCN Guidelines® for Neuroendocrine Tumors
May 10, 2021
The newest FDA-approved PET imaging agent for neuroendocrine tumors — DetectnetTM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine…
READ MORE